SynCo’s aseptic filling facility is able to fill and lyophilize a range of biopharmaceuticals which include monoclonal antibodies, nucleic acids, proteins, polysaccharides, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.
SynCo CEO Pierre Warffemius said the expansion of the Class A zone is an addition to SynCo Bio Partners’ already contract manufacturing facility in Amsterdam.